Dendreon’s Provenge steps gingerly on path to Medicare/Medicaid reimbursement
This article was originally published in Scrip
Executive Summary
As a result of the release of the Agency for Healthcare Research and Quality’s (AHRQ) 54-page draft report on the outcomes of its prostate cancer autologous vaccine, Provenge (Sipuleucel-T), Dendreon’s stock price hardly moved on the news that the agency rated its data on the treatment only of “moderate” quality.